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High-risk patients tolerate the physiologic stress-
es of conventional open repair poorly, leading to
high mortality and morbidity rates. Endovascular
aneurysm repair is an appealing option in these
patients because it avoids abdominal operation,
retroperitoneal dissection, and aortic clamping,
thereby minimizing the cardiac, pulmonary, gas-
trointestinal, and metabolic effects.1-5
We report a prospective evaluation of endovascu-
lar aneurysm repair in 116 high-risk patients who
were with large infrarenal aortic aneurysms. The first
and second halves of the study were compared to
examine the effect of increasing experience on peri-
operative mortality, perioperative morbidity, and
continuing success rates.
METHOD
This study was performed with two individual,
investigator-sponsor, investigational device exemp-
tions from the Food and Drug Administration, one for
our own custom-made device6,7 and the other for a
commercial device (Zenith, Cook, Inc, Bloomington,
Ind) that was originally developed by the team in
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Perth, Australia.8 Both protocols were approved by
the university’s human studies review board, and both
restricted endovascular treatment to patients who were
thought to be poor candidates for conventional surgi-
cal treatment. In the 3 years since the study began, our
approach has changed in several regards. The follow-
ing methods describe our current practice.
Patient selection. The eligibility criteria are list-
ed in Table I. The designation of “high risk” is made
on the basis of a variable assortment of clinical and
laboratory criteria. We do not apply a rigorous system
of preoperative testing and risk quantification9-11
because we decided that no patient would be con-
sidered too sick to undergo endovascular treatment
unless their life expectancy was less than 2 years.
Some patients have already undergone measure-
ments of cardiac perfusion and ventricular function
when they are seen, and some have not.
The patients who meet the eligibility criteria
undergo computed tomographic (CT) and angio-
graphic assessement of arterial anatomy to deter-
mine the feasibility of endovascular aneurysm repair.
The anatomic exclusion criteria have become slight-
ly less restrictive as the study has progressed. The
current criteria for the custom-made device are list-
ed in Table II. Many patients are excluded on the
grounds of a single criterion, such as the absence of
a nondilated segment of aorta between the renal
arteries and the aneurysm (a neck), but we also
weigh the combined effects of several different fac-
tors. Relative contraindications, such as a conical
neck, are more likely to be overlooked if they occur
in isolation or if they occur in the presence of press-
ing indications for endovascular repair. Fig 1 illus-
trates this point. We have less experience with the
Zenith device, and therefore, the anatomic exclusion
criteria (Table III) are slightly more restrictive.
Device description. Most of the patients in this
series underwent treatment with a custom-made
stent graft6,7 that consisted of two Z stents (Cook,
Inc) and a tubular, or tapered, sleeve of convention-
al graft fabric (Cooley Verisoft, Meadox Medicals,
Inc, Oakland, NJ). The proximal stent carries four
caudally directed barbs and four hooks. The distal
stent is unbarbed. The tapered grafts are produced
with the creation of an anastomosis between the
Table II. Anatomic exclusion criteria for the cus-
tom-made stent graft
1. Neck (proximal implantation site) that is:
a. < 10 mm in length.
b. > 28 mm in diameter.
c. thrombus lined.
d. conical (≥ 4 mm larger at its distal end).
e. severely angulated (> 80° relative to the aneurysm).
2. Iliac artery diameter < 7 mm bilaterally (after balloon
dilatation, if necessary).
3. Common iliac artery diameter > 20 mm, bilaterally.
Table I. Eligibility criteria
1. One of the following:
a. Fusiform AAA > 6 cm in diameter.
b. Fusiform AAA > 5 cm in diameter and enlarging at a 
rate > 5 mm/year.
c. Saccular AAA > 5 cm in diameter.
d. False aneurysm of the aorta.
e. Symptomatic or inflammatory AAA.
f. AAA associated with an iliac aneurysm > 35 mm in 
diameter.
2. High risk.
3. Life expectancy > 2 years.
4. Ability to give informed consent.
5. Willingness to comply with follow-up examination.
6. Absence of allergy to stainless steel, polyester, or contrast
material.
7. Absence of serious systemic or groin infection.
8. Absence of coagulopathy, unless anticoagulant induced.
AAA, Abdominal aortic aneurysm.
Fig 1. Maximum intensity projection of preoperative spi-
ral computed tomographic scan that shows conical, angu-
lated proximal implantation site (neck).
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large diameter proximal segment and the smaller dis-
tal segment. Each stent graft is sized with reference
to the findings of preoperative imaging. The proxi-
mal end of the stent graft is tethered by short suture
loops to a carrier (Fig 2) and inserted inside an 18F
(inner diameter) sheath.
Recently, we have started to use another Z
stent–based stent graft, the Zenith system. This is a
fully stented, modular, bifurcated stent graft.8 Its most
notable feature is the completely uncovered proximal
stent (Fig 3), which is intended for routine suprarenal
implantation and carries nine caudally oriented barbs
at four different levels to enhance fixation.
The version of the Zenith system that was used
in this study, the TriFab system, is inserted in three
parts: a long aortic component and two iliac com-
ponents. The aortic component has two distal dock-
ing sites, one for each iliac component. The docking
site opposite the side of aortic component insertion
(the contralateral docking site) is 30 mm shorter
than the other and carries radioopaque markers to
show its axial position within the delivery system.
When the aortic component is loaded into its
delivery system, the proximal stent is entirely
enclosed within the upstream cap of a carrier, to
which it is attached by a trigger wire. The distal stent
is attached to the shaft of the carrier by a second
trigger wire. A central cannula runs the length of the
carrier. Its downstream end is attached to the shaft
by a pinch clamp, and its upstream end is bonded to
the cap. The trunk of the stent graft and the carrier
are both loaded into an 18F (inner diameter) valved
sheath. The iliac components are delivered through
a smaller (14F), simpler version of the system used
for the aortic component. The iliac component
delivery system lacks the upstream cap and the trig-
ger wire attachments.
Stem graft sizing. The proximal diameter of
the stent graft is oversized by 4 to 6 mm relative to
the outer diameter of the neck, as measured on the
transaxial CT. The distal stent graft diameter is over-
sized by 0 to 2 mm relative to the largest diameter
of the iliac implantation site, as measured on angiog-
raphy. The length of the stent graft, or the stent graft
Table III. Anatomic exclusion criteria for the
Zenith stent graft
1. Neck (proximal implantation site) that is:
a. < 15 mm in length.
b. ≥ 28 mm in diameter.
c. thrombus lined.
d. conical.
e. severely angulated (> 60° relative to the aneurysm).
2. Iliac artery diameter < 7.5 mm on either side (after balloon
dilatation, if necessary).
3. Severe iliac occlusive disease, tortuosity, or calcification.
4. Iliac artery diameter > 20 mm at the implantation site.
5. Iliac implantation site < 14 mm in length.
6. Indispensable inferior mesenteric artery.
Fig 2. Proximal end of custom-made stent graft that
shows suture loops that tether it to delivery system.
Fig 3. Proximal end of Zenith stent graft that shows
uncovered proximal stent and its barbs.
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components, is sized with reference to the markings
on a calibrated angiographic catheter. The largest
diameter that the custom-made delivery system can
accommodate is 32 mm.
The Zenith stent grafts are selected from a
range of available sizes. The diameter of the aortic
component ranges from 20 mm to 32 mm, in 2-
mm increments. The length of the aortic compo-
nent (from the proximal end of the graft fabric to
the distal end of the contralateral docking site)
ranges from 74 mm to 132 mm, in 14-mm and 15-
mm increments. The goal in choosing an aortic
segment is to ensure that the contralateral docking
site lies as close to the aortic bifurcation as possible,
although if any doubt exists regarding the correct
length, we tend to err on the side of too short,
rather than too long.
The diameter of the iliac components range from
8 mm to 24 mm, in 2-mm increments. The lengths
range from 37 mm to 122 mm, in 17-mm incre-
ments. The goal in choosing the length of the iliac
component is to create at least 30 mm of overlap
with the common iliac artery. If there is any doubt
regarding the correct length, we tend to err on the
side of too long, rather than too short.
Insertion procedure. The basic insertion tech-
niques have been described previously for both our
custom-made stent graft6,7 and the Zenith stent
graft,8 but there have been several minor changes
during the course of this study. The current tech-
nique is subsequently described.
We expose the femoral arteries bilaterally through
oblique incisions at the level of the inguinal liga-
ments.12 This approach reflects the results of our early
experience,6 in which standard longitudinal incisions
were associated with a high rate of wound complica-
tions. Only a short segment of the proximal femoral
artery is exposed, even in the cases that require femo-
rofemoral bypass grafting. The deep and superficial
arteries are rarely exposed and are never clamped. In
the Zenith cases, femoral artery exposure is obtained
only as a means of performing femoral artery repair at
the end of the operation. The entire procedure is per-
formed through valved sheaths, which obviate the
need for arterial occlusion. These sheaths traverse the
skin through small stab wounds distal to the primary
incisions and enter the softest available areas in the
exposed portions of the femoral arteries.
The patients who have unilateral common iliac
aneurysms undergo treatment with preoperative
internal iliac embolization. We use large coils to
occlude the proximal trunks of the internal iliac
artery and leave the smaller branches patent to act
as potential routes of collateral flow, which there-
by minimizes the risk of buttock claudication.
We do not use a brachial-femoral guidewire. If the
iliac arteries are tortuous and calcified, the delivery sys-
tem is inserted over a stiff guidewire (Lunderquist,
Cook, Inc). We have never encountered a case in
which the delivery system insertion was prevented by
iliac tortuosity, and we have encountered only one
instance in which the access to the common iliac artery
could only be obtained with direct surgical exposure.13
In that case, the impediment to the delivery system
insertion was diffuse iliac stenosis, not tortuosity.
The angiographic catheter enters the arterial tree
through the femoral artery on the side opposite the
side of stent graft insertion. Unless we encounter
problems in aortic catheterization, the first intraoper-
ative angiograms are performed with the stent graft
delivery system already inside the aorta. The contrast
material is 350 mg/mL iohexol (Omnipaque,
Nycomed, Princeton, NJ). The intraoperative type I
endoleaks (around the end of the stent graft)14 are
treated with a variety of adjunctive endovascular
techniques.15 The type II endoleaks (through lumbar
or inferior mesenteric arteries) are ignored.
Suprarenal stent implantation is a routine part of
the Zenith system, which has an entire uncovered
stent at its proximal end (Fig 3). Our custom-made
stent graft also permits an uncovered portion of the
proximal stent to be implanted over the renal artery
orifices, which we do in almost every case, unless the
neck is long and healthy or the aorta has a sharp
bend at the level of renal arteries.
The entire distal segment of the custom-made
stent graft is reinforced with Wallstent. In constrast,
the Zenith stent graft is supported throughout its
length with a series of external Z stents and requires
additional support only when the common iliac
artery is tortuous. We have seen only one such case
(Fig 4), in which the implantation of a Wallstent
helped to eliminate a kink in the iliac component of
a Zenith stent graft.
Follow-up examination. Aneurysm exclusion
was assessed using serial contrast-enhanced CT
before discharge, at 3, 6, and 12 months, and annu-
ally thereafter. The patients with endoleak on the
first postoperative CT results underwent another
scan 2 weeks later. If an endoleak was present, the
patient underwent angiography and endovascular
treatment. The type I (direct perigraft) endoleaks
were treated with additional stent grafts.15 The type
II (indirect collateral) endoleaks were treated, when-
ever possible, with coil embolization of collateral
pathways.15-17
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RESULTS
Endovascular repair was considered feasible in 67%
of all the patients who were eligible for inclusion in the
study. Most of the patients (93%) who were excluded
on anatomic grounds lacked a suitable implantation
site between the renal arteries and the aneurysm.
Between June 1996 and June 1999, elective endovas-
cular aneurysm repair of abdominal aortic aneurysm
(AAA) was performed in 116 patients, with a mean
age 75 years and a mean AAA diameter of 6.3 cm. If
the aneurysms that were expanding, inflammatory,
symptomatic, anastomotic, saccular, or associated with
large iliac aneurysms (total, n = 26) are excluded, the
mean AAA diameter was 6.6 cm. The American
Society of Anesthesiologists (ASA) grade was II in
3.4% of cases, III in 65.5%, and IV in 31%. The comor-
bidities are listed in Table IV.
The procedure was performed with regional
(epidural or spinal) anesthesia in 84 cases (72.4%),
general in 29 cases (25%), and local in three cases
(2.6%). We used custom-made tapered aortomonoil-
iac stent grafts in 90 cases (77.6%), custom-made
straight aortoaortic stent grafts in 13 cases (11.2%),
and Zenith bifurcated aortobiiliac stent grafts in 13
cases (11.2%; Fig 5). Stent graft implantation was
successful in all 116 cases. None of the cases were
converted to open repair. The 116 patients who
underwent treatment included many examples of
severe arterial distortion, such as neck angulation of
more than 60° (21.6%), neck length of less than 15
mm (24%), iliac angulation of more than 90° (19.8%
of patients), and iliac aneurysm (13.8% of patients).
The mean operating time (± the standard devia-
tion) was 191 ± 65 minutes, the mean contrast vol-
ume was 154.5 ± 84.9 mL, and the mean blood loss
was 280.9 ± 374.7 mL. The mean time from opera-
tion to resumption of a regular diet was 0.72 ± 0.53
days, to ambulation was 1.08 ± 0.58 days, and to
discharge from the hospital was 4.04 ± 2.10 days.
Two patients (1.7%) died within 30 days of the
operation: one during attempted ablation therapy
for a longstanding arrhythmia and the other of
pneumonia after re-exploration of the groin wound
for infected lymph fistula. One other patient died
after re-exploration of the groin wound for infected
lymph fistula. This death occurred 3 months after
the original operation.
To illustrate the effects of evolving technique,
we have listed the perioperative complications in
Fig 4. A, Preoperative angiogram that shows angulation
of left common iliac artery. B, Completion angiogram that
shows smooth curve of left limb of graft, which contains
Wallstent.
Table IV. Comorbidity in 116 patients who
underwent endovascular repair
Comorbid conditions No. of patients
Coronary insufficiency 94
Chronic obstructive pulmonary disease 57
Congestive heart failure 39
Renal insufficiency* 25
Obesity 35
*Creatinine level, ≥1.5 mmol/dL.
A
B
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the following two groups: those that occurred in
the first half of the study and those that occurred in
the second half (Table V). The most striking dif-
ference between the two groups is in the incidence
of serious wound complications. All the patients in
the latter half of the study underwent treatment
with an oblique incision for femoral exposure.12
The only two wound complications in this group
were small areas of necrosis where deep intertrigi-
nous folds could not be altogether avoided. The
declining number of complications is apparent in
the rates of perioperative (30-day) morbidity and
mortality (Table VI). In this context, major peri-
operative morbidity was defined as a complication
that delayed discharge more than 5 days or that
required readmission within 30 days of operation.
The cases of uncomplicated endoleak were not
included. In the second half of the study (n = 58),
there were no perioperative deaths and a major
morbidity rate of 3.4%. Surprisingly, the length of
stay did not follow the same trend and rose from
3.5 days in the first half of the study to 4.5 days in
the second half.
The mean follow-up period was 15.9 ± 10.23
months (range, 0 to 34 months). The late complica-
tions are listed in Table VII. Kinking developed in
five cases. All of these cases were treated with addi-
tional Wallstents. In four of the five, the lumen was
further narrowed by mural thrombus at the kink
(Fig 6). All four patients have since undergone anti-
coagulation therapy with warfarin sodium. Two of
these patients had malignant carcinomas. There have
been no cases of complete stent graft occlusion.
Femorofemoral bypass graft occlusion has occurred
Table V. Perioperative (30-day) complications in
the first and second halves of the study
Complications First 58 patients Last 58 patients
Wound infection 5 0
Wound necrosis 4 2
Lymph fistula 2 0
Infected lymph fistula 2 0
Lymphocele 4 1
Re-exploration for hematoma 3 0
Myocardial infarction 4 0
Stroke 0 1
Renal impairment* 1 0
Renal embolism† 0 1
Digital embolism 1 0
Deep venous thrombosis 0 1
*Rise in creatinine level, >1.0 mmol/dL.
†Computed tomographic finding only.
Fig 5. A, Maximum intensity projection of spiral computed tomographic scan that shows
tapered aortomonoiliac stent graft, femorofemoral graft, and left common iliac occluder
(arrow). B, Maximum intensity projection of spiral computed tomographic scan that shows
bifurcated aortobiiliac stent graft.
A B
JOURNAL OF VASCULAR SURGERY
128 Chuter et al January 2000
twice: once as a result of a tumor-induced hyperco-
agulable state and once as a result of femoral-
popliteal bypass graft occlusion. In the first case,
thrombus was extracted with a Fogarty balloon
through an access point in the mid graft. In the sec-
ond case, thrombus within the femorofemoral graft
was lysed with urokinase.
There were three cases of proximal stent migra-
tion, all of which were treated with additional stent
grafts. Two cases were attributed to low implantation
at the original operation, followed by dilatation of the
implantation site and migration of the undersized stent
graft. The other case was attributed to inadequate
attachment of the proximal stent to the walls of a
short, angulated neck (Fig 7). In two cases, migration
was an incidental finding on follow-up imaging. In the
other case, proximal stent migration produced sec-
ondary endoleak, aneurysm expansion, and rupture.
Interestingly, this patient’s condition was never hemo-
dynamically unstable. The patient went home 3 days
after the implantation of an additional stent graft. At
the last follow-up examination, a year after the second
operation, the stent graft position had not changed
and the aneurysm had shrunk by 25 mm.
Only one late problem was not successfully treat-
ed by endovascular means. This man had no signs of
endoleak on the first CT results but was lost to fol-
low-up examination almost immediately after dis-
charge from the hospital. No other scans were per-
formed until the patient was seen at a hospital in a
different state with abdominal pain. Noncontrast
CT showed aneurysm enlargement, which prompt-
ed conventional surgical repair. At operation, the
only identifiable source of endoleak was a patent
lumbar artery.
At 2 weeks after the repair, 12 patients (10.3%)
had endoleaks based on CT results. On the basis of
subsequent angiography, three of these were type I
(around the end of the stent graft), seven were type II
(through collaterals), and two were both type I and
type II. There were no leaks of types III or IV
(through small or large holes in the graft). All the type
II leaks resolved after endovascular treatment with
additional stents, stent grafts, and embolization coils.
Only one of the nine type II leaks resolved, despite
Table VI. Perioperative (30-day) mortality and
morbidity rates for the first and second halves of
the study
First 58 patients Last 58 patients
Minor morbidity 7 (12.0%) 2 (3.4%)
Major morbidity* 12 (20.7%) 2 (3.4%)†
Mortality 2 (3.4 %) 0 (0%)
*Discharge delayed by more than 5 days.
†Significant difference between the two groups (P = .01).
Fig 6. A, Multiplanar reconstruction of spiral computed tomographic scan that shows throm-
bus lining the stent graft (arrows). B, Angiogram that shows two areas of stenosis (arrows). 
C, Angiogram after implantation of additional Wallstent and balloon dilatation.
A B C
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the embolization of collateral arteries in five patients.
Aneurysm expansion by more than 5 mm occurred in
two of the eight patients with persistent type II leaks.
Interestingly, aneurysm growth ceased after the coil
embolization of collaterals in both patients, despite
persistent endoleak on CT. One patient had a sec-
ondary type II endoleak develop when he underwent
anticoagulation therapy with warfarin sodium a year
after operation, which brought the total number of
unresolved type II endoleaks back up to nine.
The technical success rate at 2 weeks was 87.1%,
and the clinical success rate was 97.4%, as defined
by the reporting standards of the Society for
Vascular Surgery and the International Society for
Cardiovascular Surgery, North American Chapter.18
At the time of this writing, the continuing success
rate (including secondary success) was 87.9%. But
this assessment included seven cases of type II
endoleak, in which the aneurysm size did not
increase, and one case of stent graft explantation for
tuberculous aortitis, which spread from the spine. If
these cases were excluded, the continuing success
rate would be 94.8%.
The survival curve after endovascular aneurysm
repair is shown in Fig 8. Of the original 116
patients, 95 are still alive. In addition to the two
perioperative deaths and the one late related death,
there have been 18 late unrelated deaths. The most
common causes of death were myocardial infarction
(n = 5) and cerebrovascular accident (n = 6).
Renal infarcts were seen on postoperative CT in
four patients. The causes were deliberate occlusion of
an accessory renal artery (n = 2), deliberate occlusion
of the renal artery to one of two normally functioning
kidneys (n = l), and renal atheroembolism from a
pararenal aortic plaque (n = l). No new infarcts have
been seen on follow-up CT results.
DICUSSION
On the basis of these results, endovascular stent
graft implantation appears to be both safe and effec-
tive in the group of patients studied. Broader con-
clusions regarding the role of endovascular aneurysm
repair in the management of high-risk patients
depend on the answers to two related questions.
First, were these truly high-risk patients? Second, is it
worthwhile to operate on such patients, given their
limited life expectancy?
Although all of these patients had serious comor-
bidities (Table IV), we lack the data to quantify the
risk.9-11 Our routine preoperative evaluation did not
include the testing of cardiac perfusion or ventricu-
lar function, and we found that the simplest clinical
algorithms did not take account of several factors
Fig 7. A, Operative angiogram that shows left renal artery (black arrow), top of original stent
graft (black arrow), and branches of superior mesenteric artery (white arrows). This stent graft
had migrated 5 mm from its original implantation level. B, Completion angiogram after place-
ment of additional stent graft. Proximal and distal stents of stent graft are indicated with black
arrows. Branches of superior mesenteric artery are indicated with white arrows.
A B
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that would have contributed to the risk of open
repair in many of our patients, such as obesity, hos-
tile abdomen, and prior attempts at open repair.
Approximately one third of our patients had an
American Society of Anesthesiologists grade of IV,
which is more than one would expect in a convention-
al surgical series but comparable with other studies of
endovascular aneurysm repair.19,20 Nevertheless, we
think it unlikely that conventional repair would have
produced a 30-day mortality rate of 1.7% in this group
of patients. Because we applied no upper limit on the
severity of anesthetic risk, some of these patients were
very sick. Examples include: two patients with aortic
valve gradients greater than 60 mm Hg, two with ven-
tricular ejection fractions less than 20%, and one who
had been rejected for cardiac transplantation because
of too many comorbidities. A few outliers, such as
these, can have a disproportionate influence on an oth-
erwise low mortality rate.21
Several other data illustrate the high prevalence
of serious cardiac and pulmonary disease among our
patients. One example is the projected mortality rate
of 25% at 2 years, which we attribute to the ongoing
effects of the comorbid conditions rather than the
delayed effects of the operation. This rate is higher
than the projected late mortality rate of endovascu-
lar AAA repair reported by May et al.20 The differ-
ence probably reflects a higher prevalence of severe
cardiac and pulmonary disease in our series. Another
indirect indicator of high risk among the larger
group of patients considered for endovascular repair
is the fate of those patients who were refused the
operation on anatomic grounds but were otherwise
eligible. Despite a mean aneurysm diameter of more
than 6 cm, less than half of these patients subse-
quently underwent open repair, and the periopera-
tive mortality rate was 17%.
The benefits of aneurysm repair depend on the
operative mortality, the risk of aneurysm rupture, and
the life expectancy.22 Although the endovascular tech-
nique has reduced the risk of operation in high-risk
patients, limited life expectancy probably undermines
its value. On the basis of the high rate of late mortal-
ity observed in this study, we believe that aneurysm
repair is hard to justify in high-risk patients unless the
risk of rupture is high. Consequently, we do not treat
small aneurysms in high-risk patients unless they are
expanding, inflammatory, symptomatic, anastomotic,
saccular, or associated with large iliac aneurysms.
The difference in complication rates between the
first and second halves of the series shows the effect of
changes in operative technique, the most important
of which relate to femoral artery exposure.12 Most of
the complications that were experienced in the first
half of the series were wound problems. These were
not minor. The only two deaths truly attributable to
the procedure both followed re-exploration for infect-
ed lymph fistula. It appears that our patients were
prone to the development of wound infection, necro-
sis, and lymph fistula. One apparent risk factor was a
high prevalence of obesity (31%). Nevertheless, these
wound problems were avoidable, as the latter half of
the series showed. We believe that the improved
results in the latter half of the series reflect the bene-
ficial effects of increasing experience and not the
effect of chance. Other authors have observed a simi-
lar phenomenon.19,23 The results in the latter half of
our series suggest that endovascular aneurysm repair
can be accomplished with a major morbidity rate of
3.4% and a mortality rate of 0%.
We were surprised to find that a falling compli-
cation rate was not associated with a reduced hospi-
tal stay. Although the major morbidity rate fell from
20.7% to 3.4%, the postoperative stay increased from
3.5 days to 4.5 days. The explanation probably lies
in our widening referral base and practical con-
straints on discharging patients who are old and
debilitated and who live far away.
Given the high prevalence of preoperative renal
impairment (22.4%) and the volume of contrast
(154.5 mL), it is perhaps surprising that we observed
an increase in the creatinine level of more than 1
mg/dL in only one patient. Other centers have report-
ed higher rates of renal failure after the endovascular
repair of AAA.24 The lack of delayed renal impairment
or infarction is also interesting because most of the
patients in our study had one or both renal arteries
covered by portions of the proximal stent. We did not
originally take this approach. When the study began,
our policy was to place the proximal stent below the
renal arteries, unless the neck was less than 15 mm in
length or there were other reasons to believe that the
infrarenal aorta lacked a secure implantation site. Our
reluctance to implant above the renal arteries slowly
declined as it became apparent that this maneuver pro-
duced no significant short-term effects on renal func-
Table VII. Late complications of endovascular
aneurysm repair in 116 patients
Complications No. of patients
Proximal stent migration 3
Kinking 5
Stent graft occlusion 0
Femorofemoral graft occlusion 2
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tion, whereas proximal stent migration could lead
rapidly to graft occlusion, endoleak, and aneurysm
rupture. All three instances of proximal stent migra-
tion in this series were the result of infrarenal proximal
stent implantation.
The operative time, hospital stay, morbidity rate,
mortality rate, and success rate all compare well with
the results of other large studies of endovascular
aneurysm repair.19-21 Specific concerns relating to
the use of an aortomonoiliac stent graft have not
been borne out. The main weakness of the aor-
tomonoiliac approach is its reliance on a femoro-
femoral bypass graft. It appears that femorofemoral
bypass grafting has a higher patency rate in patients
with aneurysm than in patients with aortoiliac occlu-
sive disease.25 Other investigators have reported
similar findings. We have yet to see a case of stent
graft occlusion, probably because significant graft
stenosis produced symptoms that allowed its detec-
tion and endovascular treatment (Fig 6). The limita-
tions on flow rate imposed by uniiliac outflow do
not seem to be a major problem in the patients at
high risk, whose activity is more often restricted by
general debility or cardiopulmonary disease.
The rate of endoleak at 2 weeks is comparable with
the rates in other reported series.19,21,23 We decided to
attempt endovascular treatment in all the cases of
endoleak because most of our patients had large
aneurysms and aneurysm rupture is a well described
consequence of endoleak.26,27 Endoleak resolution
was seen in all of the type I endoleaks but in only one
of the type II endoleaks. Nevertheless, embolization of
collaterals does seem to have prevented aneurysm
expansion in these cases. Persistent type II endoleaks
represented the largest cause of failed repair in this
series, yet it is still not clear that type II endoleaks rep-
resent a significant risk of rupture. Recent reports sug-
gest that aneurysm pulsatility28 and expansion29,30 are
less for type II endoleaks than for type I endoleaks.
Perhaps endoleak, particularly type II endoleak,
should not be considered a clear indicator of failed
repair unless the aneurysm enlarges or ruptures, and
hence, our use of a continuing success rate (95%) that
excluded those cases of type II endoleak without
increased aneurysm diameter.
Several studies have reported high short-term 
and medium-term success rates for endovascular
repair.8,19,21,23 This study is no exception. Although
the long-term durability of the approach remains to be
proven, we believe endovascular repair is the preferred
option for high-risk patients at with large aneurysms.
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Dr Takao Ohki (Bronx, NY). I would like to thank the
organization and Dr Whittemore for giving me the oppor-
tunity to discuss this important paper.
Dr Chuter and colleagues have reviewed 116 cases of
endovascular repair of abdominal aortic aneurysms, all of
which were deemed to be high risk for standard operative
repair. The perioperative mortality rate was 3.4% for the ini-
tial experience and an impressive 0% for the more recent
cases. Endoleak was present in 10% of the cases at 2 weeks.
Eighteen patients died unrelated deaths during the mean fol-
low-up period of only 16 months. On the basis of this obser-
vation, Dr Chuter concludes that endovascular repair is safe
and effective in patients at high risk and, therefore, should be
considered the first-line treatment option for these patients.
I have several questions for Dr Chuter. We at Montefiore
also have treated patients with abdominal aortic aneurysms
who are at high risk for standard repair with a stent graft.
The common dilemma that we and others face is whether
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there is any validity in repairing an asymptomatic aneurysm
if the patient is at high risk for comorbid reasons, and if so,
at what size? A paper written by Dr Jones and his colleagues
in the British Journal of Surgery (1998;85:1382-4) reported
the analysis of the natural history of patients at high risk with
abdominal aortic aneurysms larger than 5 cm in diameter. In
this study, they found that 88% of the patients had died at the
end of the study and that the median survival rate was only
18 months. More importantly, only 35% of these deaths
were due to aneurysm rupture. On the basis of this observa-
tion, Dr Jones has concluded that elective aneurysm repair in
this group of patients is not justified because the vast major-
ity of the patients die of other causes. Can you give us your
thoughts regarding this dilemma?
One way to answer this question is to analyze what
happened to the 77 patients who were excluded from your
endovascular protocol on the basis of anatomic grounds.
How many of these patients were treated nonoperatively?
And what was the mean survival rate for the nontreated
patients? In your study, the endovascular group, 18% of
the patients treated endovascularly died during the mean
follow-up period of only 16 months. Was this number any
better than that of the nonoperated group?
You concluded that endovascular repair is safe and
effective in patients at high risk. I agree with the first part
of your conclusion. However, I have some reservation to
say that it is effective. To say it is effective, one must show
that the endovascular repair prolonged the patient’s life
longevity.
You mentioned in your manuscript that the patients
were at high risk. However, at the same time, one of your
inclusion criteria for both device protocols was that the life
expectancy for the patient had to be longer than 2 years. In
addition, the American Society of Anesthesiologists (ASA)
score was equal to or lower than III in 70% of the patients.
I have some difficulties in understanding your definition of
high risk. If their life expectancy was longer than 2 years
and if the ASA score was equal to or lower than III in the
majority of the cases, were they truly high-risk cases? Of
those 77 patients who were excluded from the endovascu-
lar protocol, how many were treated surgically? And what
was the surgical mortality rate of this group of patients?
Did they truly represent a high-risk group of patients?
Eighteen patients, that is, 16% of the patients at risk, died
during the mean follow-up period of 18 months, despite
the fact that you only included those patients who were
thought to have a life expectancy of 24 months or longer.
You mentioned that none of these deaths were related to
aneurysm rupture. Making the precise diagnosis without
obtaining autopsy may be difficult. In what percent of
these unrelated deaths were you able to obtain autopsy?
And if autopsy was not obtained, how can you be sure that
it was not aneurysm related?
Thank you very much.
Dr Timothy A.M. Chuter. Dr Ohki raises some impor-
tant points. I think he is right to question whether endovas-
cular repair or any kind of repair is justified in patients at high
risk, given their poor long-term survival rates. Obviously, a
patient has to live long enough to appreciate the benefits of
freedom from risk of rupture.
We tried to make the risk/benefit ratio favor endovascu-
lar aneurysm repair in a number of ways. First, we tried to
select patients who were going to live more than 2 years.
Second, we tried to treat only aneurysms that we believed
had a high risk of rupture, which included large fusiform
aneurysms, saccular aneurysms, perianastomotic aneurysms,
or aneurysms associated with large iliac aneurysms. Third,
we tried to keep the operative mortality low. Having
achieved those objectives, I think that operation probably
was justified.
Regarding the survival of the nonoperated group, I
am afraid I just do not have these data.
I would argue that an effective endovascular repair is
one that prevents death from aneurysm rupture and avoids
open aneurysm repair. By that criterion, we were successful
in all of the cases but one. That particular patient deprived
us of the opportunity to identify and treat the cause of
aneurysm dilatation by declining follow-up examination.
Whether these patients are really at high risk is ques-
tioned by Dr Ohki on the basis of the large number who
had an ASA class of III and of the exclusion of the patients
with a life expectancy of less than 2 years. Well, ASA III is a
pretty broad category. Other investigators have shown that
among ASA III patients are many on whom you would not
want to operate. So, I do not think that is necessarily a rea-
son to think that these were not patients at high risk. And,
in fact, if you look at the survival rate of these treated
patients, I think you see fairly good reasons to think that
they were high risk, although perhaps not so sick as the
patients followed by Jones and colleagues in the series you
quote. The number of deaths in that series from comorbid
conditions was very high, but so was the number of deaths
from aneurysm rupture. I certainly think that endovascular
repair is justified if the alternative is a 35% mortality rate
from aneurysm rupture in only 18 months.
Dr David C. Brewster (Boston, Mass). Congratulations
on your report. Certainly we share one of your conclusions,
which I believe is that this methodology is best applied to the
older patient at higher risk.
I would like your comments, though, on the potential
trap of trying to push the envelope, so to speak, in your
zeal to use an endovascular method of treatment in the
higher risk patient category. I think that in taking on
adverse and challenging anatomy, we do increase the haz-
ard of getting into technical trouble and therefore having
to convert, in which case the risk is extremely high. Can
we have your thoughts on this potential paradox?
Dr Chuter. I agree with you absolutely. An important
factor in the risk/benefit analysis is a low mortality rate
after repair. And if you have to convert high-risk patients
to open surgery, you are not going to have a lot of deaths.
So, patients who have high-risk anatomy, that is, short
implantation sites, difficult access, etc, together with high-
risk physiology, should probably be excluded.
